Vincerx Pharma, Inc. Common Stock - Asset Resilience Ratio
Vincerx Pharma, Inc. Common Stock (VINC) has an Asset Resilience Ratio of 47.80% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vincerx Pharma, Inc. Common Stock total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Vincerx Pharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Vincerx Pharma, Inc. Common Stock (VINC) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vincerx Pharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Vincerx Pharma, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.14 Million | 47.8% |
| Total Liquid Assets | $7.14 Million | 47.80% |
Asset Resilience Insights
- Very High Liquidity: Vincerx Pharma, Inc. Common Stock maintains exceptional liquid asset reserves at 47.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vincerx Pharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Vincerx Pharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Vincerx Pharma, Inc. Common Stock (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Vincerx Pharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $18.22 Million | -- |
| 2022-12-31 | 68.81% | $40.80 Million | $59.29 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $117.68 Million | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more